INmune Bio Inc.
NCM: INMBLive Quote
📈 ZcoreAI Score
Our AI model analyzes INmune Bio Inc.'s price action across multiple timeframes using regression channels and statistical scoring.
Get INMB Z-Score →About INmune Bio Inc.
Healthcare
Biotechnology
INmune Bio Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, which is in Phase II for the treatment of breast cancer. It provides XPro1595 for the treatment of Alzheimer's disease and treatment resistant depression; and CORDstrom, a cell suspension for intravenous infusion or injection comprising aseptic, allogeneic, and pooled HucMSCs. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; GOSH; and University of Pittsburg. The company was incorporated in 2015 and is headquartered in Boca Raton, Florida.
📊 Fundamental Analysis
INmune Bio Inc. demonstrates a profit margin of 0.0%, which is below the sector average, suggesting competitive pressure.
Return on Equity (ROE) is -165.2%, which indicates that capital utilization is currently under pressure.
At a current price of $1.18, INMB currently trades near the bottom of its 52-week range (1%), indicating potential value or weakness (Range: $1.09 - $11.64).
🏥 Financial Health
🔴
Profit Margin
Weak
🔴
Debt/Equity
Elevated
🔴
Return on Equity
Weak
⚠️
Beta (Risk)
Moderate Volatility
Key Financials
Market Cap
$31.37M
Trailing P/E
--
Forward P/E
-2.23
Beta (5Y)
0.89
52W High
$11.64
52W Low
$1.09
Avg Volume
440K
Day High
Day Low